Alloplex Biotherapeutics Inc

Join Us at SITC 2024 to Discover SUPLEXA’s Breakthrough Potential in Cancer Immunotherapy. As the Society for Immunotherapy of Cancer (SITC) annual meeting kicks off in Houston, we are honored that SUPLEXA, Alloplex Biotherapeutics’ groundbreaking immunotherapy platform, has been recognized among the Top 100 presentations. This recognition speaks to SUPLEXA’s potential as a new approach in the fight against solid tumors by leveraging the power of patients’ own immune cells, trained ex vivo, without genetic modification. Key Highlights to Be Presented: -Top 100 Abstract #378: Showcases SUPLEXA’s unique pharmacodynamic profile, providing key insights into its immunomodulatory effects. -Phase 1 Trial Results, Abstract #608: Final safety and efficacy outcomes from our first-in-human study, demonstrating SUPLEXA’s remarkable safety and promising clinical responses across multiple challenging cancer types. With SUPLEXA, we’re retraining patients' immune cells outside the body, restoring their natural ability to recognize and attack cancer effectively. Early data is inspiring—showing potential to benefit patients across tumor types including colorectal, renal, melanoma, breast cancer and beyond. We invite all SITC 2024 attendees to meet John Pulford and Dr. Frank Borriello at the poster presentations on Saturday, November 9th for an in-depth look at SUPLEXA’s approach and its future potential in cancer care. Let’s connect and discuss what’s possible in cancer immunotherapy. Thank you to all the collaborators, researchers and private investors who have helped make this vision a reality. We’re excited to move closer to transforming patient outcomes with SUPLEXA. #SITC2024 #SITC24 #Immunotherapy #SUPLEXA #CancerResearch #CellTherapy #CancerBreakthrough #AlloplexBiotherapeutics #Innovation #ImmunoOncology

Alloplex's Groundbreaking Cancer Immunotherapy Selected for SITC24 'Top 100' Presentation   Boston, MA — October 10, 2024. Alloplex Biotherapeutics is pleased to announce that our innovative SUPLEXA immunotherapy platform has been recognized by the Society for Immunotherapy of Cancer (SITC) for its upcoming international conference in Houston, Tx, this November. Two abstracts featuring SUPLEXA have been accepted for poster presentations, with one earning the prestigious 'Top 100' designation among 1,300 submissions. This recognition underscores the potential impact of our non-engineered, personalized cellular therapy in the fight against cancer. Key Highlights: 1- Top 100 Abstract: "Transcriptional and proteomic insights into the immunomodulatory nature of SUPLEXA cells: An autologous cellular therapy for cancers" (Abstract #378). Showcases SUPLEXA's unique pharmacodynamic effects on patient peripheral blood composition. 2- Phase 1 Trial Results: "Final safety and efficacy update of SUPLEXA-101, a First-in-Human, Single Agent Study of SUPLEXA Therapeutic Cells in Metastatic Solid Tumors" (Abstract #608). Reports outcomes from our 35-patient study testing SUPLEXA in end-stage solid tumor patients.   SUPLEXA represents a paradigm shift in cancer immunotherapy, harnessing the power of patients' own immune cells without the need for genetic engineering. Our Phase 1 trial has demonstrated an exceptional safety profile and encouraging efficacy signals across multiple tumor types. We're excited to share these groundbreaking results with the scientific community at SITC 2024. This recognition validates our innovative approach and brings us one step closer to potentially transforming cancer treatment. If you will be attending SITC, we look forward to seeing you for our poster presentations at the Immune Engineering Workshop (Thursday Nov 7th) and the Annual Meeting (Saturday November 9th). Stay tuned for more updates as we prepare to advance SUPLEXA towards Phase 2 trials.   Thanks to the authors: John Pulford, Ekaterina (Katya) Murzin , Rohit Joshi, Jeffrey Goh, Ganessan K., Dr Warren Joubert, Victoria Atkinson, Vineet Kwatra, Meena Okera, Sarwan Bishnoi, George Nisyrios, Sharron Gargosky, PhD, Frank Borriello and James Lederer   #SITC24 #SITC2024 #ImmunoOncology #Immunotherapy #ClinicalTrial #CancerTrial #CancerResearch #CellularTherapy #Alloplex #Alloplexbio #DrFrankBorriello #Autologous #NonEngineered #SUPLEXA #SUPLEXACells #SUPLEXATherapy #ColorectalCancer #RenalCellCancer #CancerBreakthrough #CancerScience #AutologousCellBasedTherapies #Innovation #biotech #Investment

Dr. Borriello will be a featured speaker at an upcoming webinar entitled "Adapting to Immuno-Oncology's R&D Challenges: Refocusing on Innate Immunity as the 'Next Big Thing' in Cancer Immunotherapy". The live webinar, being moderated by Lumanity, will bring together a diverse array of biotech with a range of platforms and modalities to modulate innate pathways towards the goal of enhancing the ability of the patient's immune system to control cancer (with or without immune checkpoint inhibitors). Date: Wednesday, October 23, 2024 At: 10:30 a.m Eastern Daylight time Register free via https://lnkd.in/efg4SJ49 #cancerprogress #alloplexbiotherapeutics #alloplex #suplexatherapy #suplexatherapeuticcells #drfrankborriello #frankborriello #lumanity #immunooncology #biotech #immunecheckpointinhibitors #cancerresearch

Our CEO, Dr. Frank Borriello, recently sat down with Immuno-oncology Insights ' Lauren C. to discuss the unique strengths of Alloplex’s autologous, non-engineered SUPLEXA platform in addressing the complexities of treating solid tumors and using a patient's own immune cells to engage multiple immune pathways.   Unlike the challenges that emerge from conventional 'off-the-shelf' allogeneic approaches, which can face rejection and limited durability, SUPLEXA's autologous approach is designed to ensure better compatibility and safety, reducing the risks associated with genetic modifications.    Dr. Borriello’s interview references initial clinical outcomes have shown promising safety and efficacy in difficult-to-treat cancers such as melanoma, lung, colorectal, and breast. Notably, several patients experienced significant improvements, with a welcome return to daily activities after exhausting other treatments. With our Pre-IND meeting completed, Alloplex is advancing toward IND submission and the next phase of clinical development.   For those following the evolution of immuno-oncology, SUPLEXA represents a promising shift in how we approach cancer treatment. Follow us to stay informed about our progress as we continue to explore the potential of cellular therapies in solid tumors. Read the full interview here https://lnkd.in/eXUdQbAV Feel free to share your thoughts and join the conversation! #SUPLEXA #ImmunoOncology #CellTherapy #Autologous #AlloplexInTheNews #CancerResearch #Biotech #Alloplex #InvestInScience #AlloplexBiotherapeutics #ImmunoOncologyInsights #LaurenCoyle #FrankBorriello

We’re delighted to welcome Paul Sowyrda to the Alloplex Biotherapeutics Corporate Board. Dr Borriello also extends his thanks to Jared Chung for his three years’ tenure on the Board.

This week's article from the Washington Post about Gen X and Millennials being at higher cancer risk than older generations "is very humbling", indeed.

Dr. Borriello is an Expert Speaker at the upcoming 5th Gamma Delta T meeting in Boston. If you're attending the conference, head to his talk to hear the latest exciting clinical developments and to meet him.

Today, we are sharing our CEOs thoughts on a recent exciting industry development

Are you attending Immuno-Oncology Xchange run by hubXchange in Boston tomorrow? We invite you to meet#AlloplexBiotherapeutics CEO @FrankBorriello. Dr. Borriello is participating in a round table and sharing his insights into the latest insights and clinical benefits from our SUPLEXA autologous #immunooncology cell therapy trial in the treatment of solid cancer tumors. Immuno-Oncology Xchange June 18, 2024, at the Hilton Boston/Woburn, MA, USA. The Xchange brings together executives from pharma and biotech to discuss the development of I-O therapies. It will cover everything from immune biomarkers, translational research, clinical development, to the tumour microenvironment. https://lnkd.in/eR4Hd9Yh #immunooncology #cancerresearch #celltherapies #suplexa #suplexatherapeuticscells #immunooncologyxchange #autologous #cancer #cellulartherapies #immunotherapy #frankborriello

Alloplex Biotherapeutics' CEO, Dr Frank Borriello is confirmed as a Speaker at the upcoming 7th Annual Next-Gen Immuno-oncology Conference in Boston, MA. Dr. Borriello will deliver an update on the SUPLEXA clinical trial entitled 'SUPLEXA therapeutic cells, a clinically de-risked cell therapy platform with unique mechanisms of action for treating solid cancers'. He will also propose a hypothesis regarding the potential benefits of a combination approach of SUPLEXA cells with ICIs for improved potential patient outcomes in the treatment of solid cancer tumors. Dr. Borriello's presentation is on Day 1 of the conference, 20th June, 2024 commencing at 11:45 AM at Hilton Boston Logan Airport Hotel, Boston, MA. #marketsandmarkets #immunooncology #SUPLEXAtherapy